Israel in talks with AstraZeneca on Covid vaccine

Yuli Edelstein / Photo: Yitzhak Harari, Knesset spokesperson, דוברות הכנסת
Yuli Edelstein / Photo: Yitzhak Harari, Knesset spokesperson, דוברות הכנסת

A team is advising Prime Minister Benjamin Netanyahu and Minister of Health Yuli Edelstein on the progress of all companies developing vaccines.

The race for a coronavirus vaccine is at its height. On Friday, Prime Minister Benjamin Netanyahu and Minister of Health Yuli Edelstein announced the signing of an agreement with US pharmaceuticals company Pfizer, and it's not the only one. "Globes" has learned that negotiations are taking place with British company AstraZeneca. AstraZeneca is in the midst of a Phase III trial in the UK and other countries after its trial in the US was halted because of the suspicion of side effects in one of the volunteers. The US trial is expected to resume shortly, as is a trial by Johnson & Johnson which was halted in similar circumstances.

In addition to the agreement with Pfizer and the talks with AstraZeneca, Israel has also secured a supply of vaccines from Moderna, which is expected to announce within the next few weeks, perhaps even next week, the efficacy results of the Phase III trial of the vaccine it has developed. Other companies that could publish results in the coming months are German company CureVac and US company Novavax.

In Israel's chase after a vaccine, a small team has been set up to examine the progress of all the companies involved in developing coronavirus vaccines around the world and to report to Netanyahu and Edelstein. Netanyahu's approach is to strive for an agreement with every company that demonstrates progress towards producing a vaccine, with the aim of procuring all at once enough vaccines for the entire population.

AstraZeneca and Johnson & Johnson are developing coronavirus vaccines using a technology different from that of Pfizer and Moderna. The idea is to engineer genetically a virus that causes a cold in chimpanzees, but not in human beings, such that it will not actively cause a disease but on the other hand it will present the spike that is characteristic of the coronavirus. Since the technologies are different from each other, Pfizer's success has fewer implications for AstraZeneca and Johnson & Johnson than it does for Moderna, but there is cause for optimism about all the vaccines, since Pfizer's data seem to show that in principle the disease is responsive to a vaccine.

AstraZeneca, which is developing its vaccine in collaboration with the University of Oxford, is first of all committed to the British market, and it has already signed agreements with the EU and the US, and has given a production license to an Indian company for supply to the Indian market. The company said in the past that it was gearing up to provide some three billion doses of the vaccine (it did not say within how much time) if it proved effective and safe.

Published by Globes, Israel business news - en.globes.co.il - on November 15, 2020

© Copyright of Globes Publisher Itonut (1983) Ltd. 2020

Yuli Edelstein / Photo: Yitzhak Harari, Knesset spokesperson, דוברות הכנסת
Yuli Edelstein / Photo: Yitzhak Harari, Knesset spokesperson, דוברות הכנסת
Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Isracard shareholders approve acquisition by Delek

For the deal to go through, approval is now needed from the Supervisor of Banks and the Israel Competition Authority.

Air Canada Photo: Shutterstock Air Canada to resume Israel flights in June

The Canadian airline will resume Toronto-Tel Aviv flights on June 8 and Montreal-Tel Aviv flights in August.

NICE CEO Scott Russell credit: SAP NICE Systems falls sharply on disappointing 2025 guidance

NICE sees $693-703 million revenue in the first quarter of 2025, up 6% from the corresponding quarter of 2024, with non-GAAP earnings per share of $2.78-2.88 - 3.8% below the analysts' consensus for revenue and 2.4% below for profit.

Tel Aviv credit: Shutterstock Urban renewal plan approved in heart of Tel Aviv

The plan for the Hahashmal neighborhood opposite the Old Central Bus Station includes a 30-floor tower.

Smartshooter credit: Smartshooter Germany buys Kibbutz Yagur's Smartshooter AI sights

The product family includes systems mounted on personal rifles, remotely controlled systems, and systems carried by vehicles, robots, and even drones.

Chinese ship in Suez Canal credit: Suez Canal Authority Direct shipping to Israel could resume soon

The first shipments of vehicles are likely to reach Israel via the Suez Canal in the coming months.

Sde Dov credit: Guy Yehieli Sde Dov land prices down over 40%

Four huge tenders for almost 4,000 homes, which have been successfully marketed in the north Tel Aviv district, reflect prices over 40% lower than in 2022.

Wix president Nir Zohar credit: Alan Tzatzkin Wix provides cautious 2025 guidance after strong 2024

The Israeli website building platform company reported its first-ever GAAP operating profit in 2024.

Saar Yoskovitz and Gal Shaul  / Photo: Augury Israeli industrial AI co Augury raises $75m

The new round represents an increase in valuation for Augury, which maintains its position as a ‘unicorn’ startup.

Eitan Yochananof and Eyal Ravid credit: Eyal Izhar and Tali Bogdanovsky Regulator indicts Victory, Yochananof CEOs over price fixing

The Israel Competition Authority today issued first indictments, following the food price fixing investigation.

Shekel credit: Shutterstock Vladirina 32 Shekel gains continue as Gaza talks progress

The shekel continues to trade at its strongest levels against the dollar since early 2023.

New York credit: Shutterstock Tel Aviv - New York fares stay high despite US airlines return

Ticket prices to the US will continue to cost at least $1,200 return, according to Ophir Tours, with most fares ranging between $1,500 and $2,000, or even more.

Greenfield Partners team credit: Eyal Toueg Greenfield Partners closes $400m third fund

The funds were raised from institutional investors in Israel, the US, Europe and Asia and brings the total funds under management to more than $1 billion.

Blockaid founders Ido Ben-Natan and Raz Niv credit: Liron Weissman Israeli onchain security co Blockaid raises $50m

Blockaid protects the largest companies building onchain, including Coinbase, Metamask, Stellar, Uniswap, and World App.

Air Haifa  credit: ATR Air Haifa to launch Paphos flights

New Israeli airline Air Haifa will launch a new route between Haifa and Paphos in Cyprus on April 3, 2025 with six weekly flights.

Bladeranger Deepsolar credit: PR Bladeranger divests Deepsolar to Painreform in strategic move

Deepsolar, acquired by Bladeranger in early 2023, is a sophisticated software solution designed to optimize the management of photovoltaic solar energy fields.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018